Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy, Safety and Tolerability of Eltrombopag Olamine (SB-497115-GR), a Thrombopoietin Receptor Agonist, Administered for 6 Months as Oral Tablets Once Daily in Adult Subjects With Previously Treated Chronic ITP
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Acronyms RAISE
- Sponsors GlaxoSmithKline; GSK
- 22 May 2014 New trial record